| Document |
Document Title |
|
WO/2019/173243A1 |
Disclosed herein are embodiments of polycyclic aromatic compounds and methods of making and using the same. Various different types of polycyclic ring systems are disclosed, including, but not limited to, polymeric aromatic compounds (e....
|
|
WO/2019/170572A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2019/169479A1 |
Compounds or pharmaceutical acceptable salts thereof of Formula (I), in which RM have the meaning described herein and pharmaceutical compositions thereof useful as antimicrobial and/or adjuvant:
|
|
WO/2019/171277A1 |
The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particularly, ...
|
|
WO/2019/166619A1 |
The present invention relates to sulfonylureas and sulfonylthioureas of formula (I) comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4- positions relative...
|
|
WO/2019/166270A1 |
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...
|
|
WO/2019/168378A1 |
The present specification relates to a heterocyclic compound of formula 1 and an organic light emitting device comprising same.
|
|
WO/2019/166269A1 |
The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the laye...
|
|
WO/2019/168140A1 |
Provided are an amide compound represented by general formula [I] or a salt thereof, an agricultural and horticultural microbicide containing the amide compound or a salt thereof as an active ingredient, and a method of using the agricul...
|
|
WO/2019/166578A1 |
The present invention relates to the field of catalytic hydrogenation and to the use of ruthenium complexes having a bidentate diphosphine ligand or two monodentate phosphine ligands, two carboxylate ligands and optionally a diamine liga...
|
|
WO/2019/159596A1 |
Provided is a method for preparing a coupled body represented by general formula (3), the coupled body being obtained by reacting a compound represented by general formula (1) and a compound represented by general formula (2) in the pres...
|
|
WO/2019/160315A1 |
The present invention relates to a heterocyclic compound of formula 1 and an organic light emitting device comprising the same.
|
|
WO/2019/157020A1 |
In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of trea...
|
|
WO/2019/153954A1 |
Disclosed are a multi-substituted benzene compound having biological activity, a preparation method therefor, and an application thereof. The compound of the present invention has good biological activity and the activity of inhibiting t...
|
|
WO/2019/154412A1 |
Provided are a new antimicrobial agent compound as shown in the following general formula (I), a pharmaceutically acceptable salt thereof, an ester thereof, a prodrug thereof, a solvate thereof, a deuterated compound thereof, or a stereo...
|
|
WO/2019/153373A1 |
Disclosed is a method for synthesizing a 2-benzylidene tetrahydrothiophene derivative, the method comprising the following step: reacting a (cyclopropyl ethynyl) aromatic cyclic compound as shown in formula (I) with a sulfur source under...
|
|
WO/2019/154949A1 |
The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
|
|
WO/2019/154974A1 |
The present invention discloses thermally stable free thiophene croconaine dyes of formula (I), where R1-R4 are 1-20C alkyl or alkenyl groups, and their even more thermally stable complexes with anthracenyl-tetralactam macro molecules, w...
|
|
WO/2019/154950A1 |
The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
|
|
WO/2019/147074A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting device using the same.
|
|
WO/2019/143529A1 |
Engineered promiscuous biotin ligases and methods of using them in proximity labeling are described. In particular, the invention provides novel biotin ligase variants having increased promiscuous biotinylation activity capable of proxim...
|
|
WO/2019/141229A1 |
The present invention involves compounds as PPAR agonists and applications thereof. The compounds involved are novel peroxisome proliferator-activated receptor (PPAR) γ receptor agonists and can inhibit the production of mitochondrial r...
|
|
WO/2019/144132A1 |
Described herein are compounds that are estrogen receptor modulators of formula I' Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen rece...
|
|
WO/2019/143057A1 |
The present invention provides an acridine derivative represented by chemical formula (1) and an organic light-emitting diode comprising same.
|
|
WO/2019/128849A1 |
The present invention relates to an organic compound and application thereof in an organic electronic device, especially organic electroluminescent diodes. The present invention further relates to an organic electronic device comprising ...
|
|
WO/2019/131922A1 |
The present invention provides a compound that has β2-adrenergic receptor antagonist activity and carbonic anhydrase-inhibitory activity, and that exhibits excellent ocular antihypertensive activity. Specifically provided is a compound ...
|
|
WO/2019/122265A1 |
The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerativ...
|
|
WO/2019/124537A1 |
Provided is an agricultural and horticultural fungicide manifesting a high control effect against a wide range of plant pathogens. The compound represented by formula (1): (in the formula, each symbol is as described in the specification...
|
|
WO/2019/124261A1 |
Provided is a Rotigotine-containing patch having a support layer and an adhesive layer, wherein the adhesive layer contains Rotigotine and/or a pharmaceutically acceptable salt thereof, and further contains a styrene-based thermoplastic ...
|
|
WO/2019/124538A1 |
Provided is an agricultural and horticultural fungicide exhibiting a high control effect against a wide range of plant pathogens. A compound represented by formula (1) or a salt thereof (in the formula, each symbol is as defined in the d...
|
|
WO/2019/124903A1 |
An organic light emitting device comprising a compound represented by formula 1 as a light emitting auxiliary layer material and an electronic device comprising the same are disclosed. As the compound represented by formula 1 is comprise...
|
|
WO/2019/122151A1 |
The present invention relates a compound of formula (I) in Z-isomer form (Z-(l)) or a compound of formula (I) in E-isomer form (E-(l)) wherein: R2 is a radical of formula (II) and of formula (III); X1, X2, X3, X4 and X5 are CR3 and N; Y1...
|
|
WO/2019/120099A1 |
The present invention relates to an organic mixture and the use thereof in an organic electronic device. The organic mixture comprises organic materials H1 and H2, wherein H1 is a compound as shown in the following general formula (1), a...
|
|
WO/2019/115577A1 |
The present application relates to a specific fluorene derivative, to its use in an electronic device and to an electronic device comprising said fluorene derivatives. Further, the present application relates to a process for the prepara...
|
|
WO/2019/115781A1 |
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...
|
|
WO/2019/110427A1 |
Compounds of the formula (I) wherein the subsitiuents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2018/151861A9 |
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, pr...
|
|
WO/2019/110137A1 |
The present invention relates to o-phenoxy and o-benzyloxypropylamino derivatives (I) having pharmacological activity towards the α2δ subunit, in particular the a2S-1 subunit, of the voltage-gated calcium channel, to processes of prepa...
|
|
WO/2019/109458A1 |
Disclosed are an organic monomolecular white light material, a preparation method therefor, and an OLED device. The organic monomolecular white light material has room temperature phosphorescence emission properties in a solid state, and...
|
|
WO/2019/107394A1 |
The present invention addresses the problem of providing a liquid crystal compound that satisfies at least one physical property including a low minimum temperature for the liquid crystal phase, a low viscosity, a suitable optical anisot...
|
|
WO/2019/105234A1 |
The present invention relates to an aromatic compound, a pharmaceutical composition comprising the compound, and a method for preparing the compound and an intermediate thereof. The present invention further relates to use of the compoun...
|
|
WO/2019/108800A1 |
The invention relates to compounds that promote hematopoietic regeneration. The invention further relates to methods of promoting hematopoietic regeneration using the novel compounds of the invention.
|
|
WO/2019/106029A1 |
The present invention relates to norbornadiene compounds (Formula I), and the corresponding quadricyclane compounds (Formula III). The compounds are to be included in a molecular thermal systems (MOST), and to be used for storing solar e...
|
|
WO/2019/102054A1 |
Non-glycosidic analogues of alpha-galactosylceramide of formula (I), wherein A, Z, Ra, Rb and Rc have the meaning indicated in the description, as NKT cell activators.
|
|
WO/2019/098796A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2019/098773A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2019/087548A1 |
Provided is a fluorine-containing ether compound which is capable of forming a lubricating layer that has excellent wear resistance even if the thickness thereof is thin, and which is suitable as a material for a lubricant for magnetic r...
|
|
WO/2019/086707A1 |
The present invention relates to a method of reducing the number or percentage of pluripotent stem cells or of enriching differentiating or differentiated cells in a cell population comprising pluripotent stem cells and differentiating c...
|
|
WO/2019/087028A1 |
Provided are IDO1 inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.
|
|
WO/2019/087129A1 |
The invention relates to compounds of formula I and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/ma...
|
